Perioperative Nivolumab Does Not Sacrifice QoL in NSCLC

Perioperative nivolumab in eligible patients with resectable non-small cell lung cancer offers improved survival outcomes and preserves quality of life, new data show.
Medscape Medical News

source https://www.medscape.com/viewarticle/perioperative-nivolumab-does-not-sacrifice-qol-nsclc-2025a1000nl9?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?